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Extracellular nucleotides are important mediators of activation, triggering various
responses through plasma membrane P2 and P1 receptors. P2 receptors are further
subdivided into ionotropic P2X receptors and G protein-coupled P2Y receptors. P2X4 is
an ATP-gated cation channel broadly expressed in most tissues of the body. Within the
P2X family, P2X4 has a unique subcellular distribution, being preferentially localized in
lysosomes. In these organelles, high ATP concentrations do not trigger P2X4 because of
the low pH. However, when the pH increases to 7.4, P2X4 can be stimulated by intralysosomal ATP, which is in its active, tetra-anionic form. Elucidation of P2X4, P2X3 and
P2X7 structures has shed some light on the functional differences between these
purinergic receptors. The potential interaction between P2X4 and P2X7 has been
extensively studied. Despite intensive effort, it has not been possible yet to determine
whether P2X4 and P2X7 interact as heterotrimers or homotrimers at the plasma
membrane. However, several publications have shown that functional interactions
between P2X4 and P2X7 do occur. Importantly, these studies indicate that P2X4
potentiates P2X7-dependent activation of inﬂammasomes, leading to increased release
of IL-1b and IL-18. The role of P2X4 in various diseases could be beneﬁcial or deleterious
even though the pathophysiological mechanisms involved are still poorly deﬁned.
However, in diseases whose physiopathology involves activation of the NLRP3
inﬂammasome, P2X4 was found to exacerbate severity of disease. The recent
production of monoclonal antibodies speciﬁc for the human and mouse P2X4, some of
which are endowed with agonist or antagonist properties, raises the possibility that they
could be used therapeutically. Analysis of single nucleotide polymorphisms of the human
P2RX4 gene has uncovered the association of P2RX4 gene variants with susceptibility to
several human diseases.
Keywords: P2X4 receptor, P2X7 receptor, purinergic receptor, innate immunity, inﬂammasome, NLRP3, ATP,
anti-P2X4 mAb
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INTRODUCTION

STRUCTURE OF THE P2X4 RECEPTOR

Extracellular adenosine triphosphate (ATP) is a neurotransmitter
in the central and peripheral nervous system, and a mediator of
inﬂammation in the immune system. It can also trigger a large
variety of responses in different cell types that express various
types of purinergic receptors (1, 2). These receptors belong to
three different groups: P1, P2X and P2Y. Four P1 receptor
subtypes (A1, A2A, A2B and A3) are G-protein coupled receptors
that bind adenosine, while eight human P2Y receptors
(P2Y1,2,4,6,11,12,13,14) bind ATP or alternative purine
nucleotides such as ADP (P2Y1,P2Y12,P2Y13), UTP (P2Y2,
P2Y4), UDP (P2Y6,P2Y14) and UDP-glucose (P2Y14) (1–4).
Seven P2X receptors (P2X1 to P2X7) are ATP-gated cation
channels that can trigger numerous biological functions in
normal and diseased tissues after ligation by extracellular ATP.
In this review, P2X4 is often compared to P2X7 because the
two receptors are closely related (5) and they play an important
role in immune cell activation.

Cloning of the seven P2X receptors and the determination of
crystal structures of several P2X have vastly improved our
knowledge of P2X structure-functions relationships (6). The
P2X receptor structure consists of three subunits that form a
stretched trimer, supporting three ATP-binding sites (1). P2X
receptor subunits associate to form homo- or heterotrimers,
w h i c h d i ff e r b y t h e i r e l e c t r o p h y s i o l o g i c a l a n d / o r
pharmacological properties (7). Each subunit has intracellular
N- and C-termini linked by two transmembrane helices (TM1
and TM2) to a large extracellular ectodomain, which forms an
ATP-binding pocket with another P2X ectodomain. The
determination of crystal structures of an N- and C- termini
truncated zebraﬁsh P2X4 receptor without ATP (8) or bound to
ATP (9) revealed for each subunit an original new fold called
“dolphin”, comprising a body, head dorsal ﬁn, right and left
ﬂippers and tail corresponding to the transmembrane helices
(Figure 1A). The latter are structured as a-helices with the TM1

A

B

C

FIGURE 1 | Zebraﬁsh P2X4 receptor structure. (A) The P2X4 receptor is composed of 3 “dolphin”-like subunits, comprising a body, head, dorsal ﬁn, right and left
ﬂippers and tail. Each “dolphin”-like subunit is shown in a different color (purple, yellow and blue). (B) Crystal structure of zebraﬁsh P2X4 receptor showing 3 subunits
(in purple, yellow and blue). Each subunit has transmembrane (TM)1 and TM2 a-helices and long ectodomains. The gray dotted areas in (A, B) indicate the
presumptive plasma membrane location in which the receptor is inserted. (C) View from above of the crystal structure of zebraﬁsh P2X4 receptor showing a closed,
apo state P2X4 receptor and an ATP-bound, open state P2X4 receptor. Images (PDB ID 4DW0 and 4DW1) were obtained from the SWISS-MODEL Repository (10).
4DW0 indicates crystal structure of the ATP-gated P2X4 ion channel in the closed, apo state at 2.9 Angstroms. 4DW1 shows crystal structure of the ATP-gated
P2X4 ion channel in the ATP-bound, open state at 2.8 Angstroms.
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binding site, we refer the readers to the excellent article by
Hattori et al. (9).
The fate of desensitized P2X4 was shown to depend on its
recycling from the plasma membrane to intracytoplasmic acidic
organelles (12). Convincing studies demonstrated that P2X4 is
re-sensitized at acidic pH and that P2X4 re-sensitization is due to
protonation/deprotonation of histidines in the extracellular
domain. However, re-sensitization of P2X4 receptor at acidic
pH is inhibited in the presence of ATP and is dependent on ATP
concentrations (12). In lysosomes, the low pH (pH 5) should
facilitate the release of bound ATP from P2X4 but the high
concentrations of ATP in these organelles may block this
process. Thus, additional mechanism(s) such as spatial or
functional segregation might intervene to protect ATP-P2X4
complexes from lysosomal ATP (12).

located outside the TM2, which delineates the ion-conducting
pore (Figure 1B). The binding of extracellular ATP to P2X
receptors induces the opening of the receptor allowing the entry
of Ca2+ and Na+ and the efﬂux of K+ (Figure 1C). Schematically,
the P2X receptors differ by their sensitivity for ATP and their
kinetics of desensitization. Thus, P2X1 and P2X3 have the
highest sensitivity for ATP (EC50 = 1 mM) and fully desensitize
rapidly; while P2X2, P2X4 and P2X5 receptors have an
intermediate sensitivity for ATP (EC50 ≅ 3-10 mM) and
desensitization. The P2X7 receptor differs prominently from
the other P2X receptors in that it is activated at higher
concentrations of ATP (EC 50 = 0.5-1 mM) and does
not desensitize.
The three ATP binding sites of a homotrimeric P2X4 were
identiﬁed by analysis of the crystallographic structures (9). Each
binding pocket is nested between the upper domain of one
subunit and the lower domain of the adjacent subunit (Figure
2). The bound ATP molecule has a U-shaped structure and the
negatively charged phosphate groups form salt bridge and
hydrogen bonds with several basic and polar residues from the
upper and lower domains of the two subunits. The adenine of
ATP is deeply inserted into the ATP-binding site and forms three
hydrogen bonds with the side chain of T189 and the carbonyl
oxygen atoms of K70 and T189 (9). Additional hydrophobic
interactions occur between adenine and leucine 191 in the lower
body and isoleucine 232 of the lower ﬁn. The ribose of ATP
interacts with leucine 217 in the dorsal ﬁn by hydrophobic
interactions. For more details and an illustration of the ATP

STRUCTURE/FUNCTION RELATIONSHIPS
OF DIFFERENT P2X RECEPTORS
Analysis of the structure of the human P2X3 receptor (13) and
the rat P2X7 receptor (11), determined by X-ray and cryoelectron microscopy, respectively, unraveled several
characteristic structural features of P2X3 and P2X7 without
ATP (closed pore), with ATP-bound (open pore), and with
ATP-bound (closed pore) but desensitized. These structures
were very informative because they allowed the visualization of

FIGURE 2 | Schematic comparison of the desensitizing P2X4 receptor with the non-desensitizing P2X7 receptor (adapted from Figure 7 of McCarthy et al. (11).
(Top panel) Hypothetical schematic ﬁgure of the P2X4 receptor in Apo state, Open state and Desensitized state. (Bottom panel) P2X7 receptor in Apo state and
Open state. Black rectangles symbolize ATP molecules. As shown by McCarthy et al., the lack of desensitization of P2X7 is due to the stability of the cytoplasmic
cap and to the palmitoylated residues of the C-cysteine anchors, which should stabilize the cytoplasmic cap and maintain TM2 in an open conﬁguration (11).
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Another major ﬁnding in the cytoplasmic part of the P2X7
structure corresponds to a novel original fold called the ballast
domain (11), which comprises a dinuclear zinc ion complex and
a high afﬁnity binding site for GDP/GTP (Figure 2).
Importantly, P2X7 construct lacking the ballast domain was
shown to have gating properties identical to wild-type P2X7,
demonstrating that the ballast domain is not involved in cation
channel activity (11). However, the C-terminal region of P2X7
controls several biochemical pathways triggered after P2X7
stimulation [reviewed in Costa-Junior et al. (14)] and interacts
with various proteins [reviewed in (15, 16)]. The ballast domain
encoded by exon 13 was only found in the P2X7 receptor and in
none of the other P2X receptors.

cytoplasmic residues which were truncated in the apo and ATPbound structures of zebraﬁsh P2X4 (9). Differences between the
closed and open state of P2X3 showed that the b-0 and b-1
strands of the N-terminus of one protomer and the beta sheet of
the C-terminus of the next protomer interact to create a
“cytoplasmic cap” involved in the maintenance of the open
state. This cytoplasmic cap was found only in the ATP-bound
open state of P2X3, indicating that it is unfolded in the apo P2X3
and desensitized P2X3 states. The opening of the pore is mediated
by a rotation of the TM2 domain in an “iris-like movement”, with
a change in TM2 from an a-helix to a 310 helix (13). Importantly,
the transition from the open to the desensitized state results in the
unfolding of the cytoplasmic cap, the recoiling of the TM2
domain upward, and the closing of the pore (13). This was
described by Mansoor et al. (13) as the “helical recoil” model of
receptor desensitization. The recent elucidation of the full length
P2X7 receptor structure was a major breakthrough and revealed
the overall organization of the cytoplasmic region and the
functions of various domains (11). In particular, the lack of
desensitization of P2X7 after ATP-binding is explained by the
stability of the cytoplasmic cap formed by the b−0/b-1 sheet
located at the N-terminus of each promoter in interaction with
the b 15 sheet of the C-terminal end of the other protomer (11).
Thus, in the ATP-bound P2X7 receptor, the three b-sheets of the
cap overlay the open cytoplasmic pore delimited by the three
TM2 regions. The stability of the cytoplasmic cap, compared with
its counterpart in human P2X3, was found to be due to a region of
P2X7 containing palmitoyl moieties: 4 cysteines (C362, C363,
C374 and C377) and one serine (S360) (11). McCarthy et al. (11)
showed that the palmitoylated residues are required for
precluding P2X7 desensitization (Figure 2). They performed
two different experiments, in which they deleted the 18-aminoacid long C-cysteine anchor from P2X7 or mutated all
palmitoylable residues to alanine to preclude palmitoylation of
the receptor. The modiﬁed P2X7 constructs were then expressed
in Xenopus oocytes and compared to wild-type P2X7 receptor
after stimulation with ATP. The two forms of modiﬁed P2X7
desensitized nearly completely while the wild-type receptor did
not (11). Thus, the palmitoylated residues of the C-cysteine
anchor play a major role in preventing desensitization of P2X7
(Figure 2). In the crystal structure, the palmitoylated moieties
bound to 4 cysteines (C362, C363, C374 and C377) and one
serine (S360) in the C-cysteine anchor and to one cysteine (C4) at
the N terminus to anchor these segments into the
intracytoplasmic face of the plasma membrane, which should
stabilize the cytoplasmic cap and maintain TM2 in the open
conﬁguration (11). Thus, cytosolic cap stability plays a major role
in lack of desensitization of P2X receptors (Figure 2). Since P2X4
has a pattern of desensitization intermediate between P2X3
(rapid) and P2X7 (no desensitization), one may hypothesize
that the potential P2X4 cap stability is between these two
patterns (Figure 2). However, structural information on the
existence of a P2X4 cytoplasmic cap is missing, as X-ray
structures of P2X4 were obtained with a truncated P2X4
receptor lacking the intracellular N- and C-terminal regions
involved in cap formation.

Frontiers in Immunology | www.frontiersin.org

PORES ASSOCIATED WITH P2X
RECEPTORS
Upon prolonged ATP stimulation, several P2X receptors lead to
opening of a large non-selective membrane pore that is
permeable to molecules of molecular mass up to 900 Daltons.
Two hypotheses have been proposed to explain pore formation:
(1) P2X receptors possess an intrinsic capacity to dilate and form
the pores; (2) pore formation involves additional molecules such
as membrane hemichannels, i.e. pannexin-1 (17), connexin 43
(18) or anoctamin 6 (19) for the P2X7 receptor. However, in
mice deﬁcient for pannexin-1 or connexin 43, stimulation of
P2X7 still triggers the formation of non-selective pores, showing
that these hemichannels of macrophages are dispensable (20).
The current controversies with regards to the permeability to
large cations of P2X7, P2X2 and P2X3 following ATP
stimulation have been recently reviewed elsewhere (21).
Three P2X receptors have the capacity to open non-selective
pores after prolonged ATP stimulation, P2X2 (22–24), P2X4
(22–24), and P2X7 (25). Two teams (22–24) studied P2X4
receptors stimulated by ATP, in neurons or expressed
heterogously in HEK cells or Xenopus oocytes. Khakh et al.
(22, 23) found that after prolonged exposure to ATP, an initial
current (I1) is followed by a slower current (I2), which developed
quickly and reached a peak with an amplitude 150-300% of that
of I1. In addition, they showed that I2 corresponded to an ion
permeability increase of P2X4 receptors, allowing cations larger
than Na+ to permeate into the cells. This increase in permeability
was evidenced with studies using N-methyl-D-glucamine
(NMDG+) or a propidium-dye, YO-PRO-1. Similarly, Virginio
et al. (24) found that prolonged stimulation of P2X4 by ATP
leads to an increase in permeability allowing cations as large as
YO-PRO-1 (376 Daltons) to enter the cells. In contrast to P2X7,
both groups found that P2X4-induced opening of the macropore
was not associated with cell death. The results in favor of pore
dilation of P2X receptors were obtained by patch-clamp
electrophysiology (22–24) using NMDG+, a large synthetic
organic cation, outside the cell, and Na + inside. Brief
stimulation of P2X4 receptors by ATP opens a pore that is
more permeable to Na+ than NMDG+. During prolonged
activation of P2X4 by ATP, reverse potentials (Vrev) shift
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toward more positive values, indicating an increase in NMDG+
permeability. However, Li et al. (26) demonstrated that changes
in Vrev measured in bi-ionic NMDG+out =Na+in solutions were not
due to a time-dependent increase in channel permeability but to
a large modiﬁcation in intracellular ion concentrations, i.e. a
decrease in intracellular Na+ and accumulation of NMDG+ from
0 mM to 200 mM. While these studies challenge the pore dilation
model, they show that the channels are permeable to large
cations like NMDG+.
In primary murine microglia and murine microglial cells,
prolonged exposure to 100 mM ATP stimulates the opening of a
large P2X4 pore (27). Since P2X4 and P2X7 are expressed by
murine microglial cells, the authors compared the P2X4d e p e n d e n t a n d P 2 X 7 - d e p e n d e n t m a c ro p o re s u s i n g
pharmacological inhibitors and ivermectin, an allosteric
positive potentiator of P2X4. They found that formation of
both macropores in microglia leads to YO-PRO-1 uptake, but
only P2X7 activation triggered membrane blebbing and cytolytic
death (27). LPS-stimulated macrophages from wild-type and
P2X7-deﬁcient mice were stimulated with 10 mM ATP or with 10
mM ATP plus 1-3 mM ivermectin (28), and the release of mature
IL-1b was observed in the supernatants of macrophages from
P2X7-deﬁcient mice stimulated with ATP plus ivermectin only.
These results demonstrate that P2X4 can also trigger this
biochemical pathway in the absence of P2X7.
While numerous studies have been performed to identify the
molecular components involved in the formation of the nonselective pore(s) following P2X7 stimulation, disagreements still
remain (21, 25). In the case of P2X4, the preliminary evidence for
the formation of a non-selective, non cytotoxic pore requires
additional experimental proof.

such as microglia, vascular endothelial cells and macrophages. In
addition, they identiﬁed motifs in the N-and C-termini which are
required to sort the P2X4 to lysosomes. The L22 and I23
mutations to alanine, at the N-terminus, increased the amount
of P2X4 at the plasma membrane (32). Similarly, mutations of
the tyrosine-motif (Y378XXGL) at the C-terminus of P2X4
decreased the levels of P2X4 in the lysosomal compartment.
However, when the di-leucine and tyrosine motifs were mutated
simultaneously, a major increase of P2X4 at the plasma
membrane was observed, suggesting that the N- and Ctermini participate in endocytosis and targeting of the P2X4
receptor (32). They also convincingly showed that P2X4 is
protected from proteolysis by 6 N-linked complex
oligosaccharides (32).
Interestingly, the lysosomal localization of P2X4 coexists with
the presence of ATP in lysosomes of astrocytes (33), microglia
(34) and hepatocytes (35).
Huang et al. (36) showed that the highest concentrations of
ATP are found in lysosomes and mitochondria. In addition,
using whole-lysosome patch clamp, these authors demonstrated
that the lysosomal P2X4 is activated by luminal ATP when the
pH was raised to 7.4 (36). These results suggest that, under
physiological conditions, the high levels of ATP and P2X4
receptor in lysosomes do not lead to P2X4 activation because
the lysosomal pH is between 3.5 and 5.0 and ATP is not in its
active, tetra-anionic form at this low pH. These results are in
agreement with the ATP-P2X4 receptor crystallographic
structures showing that the a, b and g negatively-charged
phosphate groups of ATP interact with highly conserved basic
and polar amino-acids of two subunits of P2X4 (9). The presence
of high levels of ATP in lysosomes is due to the vesicular
nucleotide transporter (VNUT)/SLC17A9, which is present in
the lysosomal membrane and transports ATP across it (37).
Silencing of VNUT/SLC17A9 in a mouse cell line induced a
dramatic decrease of the ATP concentration in lysosomes, and
the accumulation of lipofuscin in lysosomes, leading to cell death
(37, 38). In addition, since P2X4 can be triggered by intralysosomal ATP as the pH increases (36, 37), Cao et al. (39)
determined that P2X4 was the Ca2+-channel involved in the
fusion of late endosomes and lysosomes. They showed that P2X4
stimulation released Ca2+, which activated calmodulin. As a
consequence, calmodulin associated with P2X4 and promoted
vesicle fusion (39).
An original strategy was recently developed by Xu et al. (40)
to follow the cellular distribution of P2X4 among various
compartments. They produced a pH-sensitive tagged P2X4
receptor by grafting the pHluorin protein within its
extracellular domain (40). The P2X4-pHluorin construct was
used to transfect HEK 293 cells, an immortalized microglial cell
line, and primary hippocampal neurons and alveolar type-II
cells. The authors incubated cells with 25 mM NH4Cl to increase
the pH of acidic compartments, causing the ﬂuorescent P2X4pHluorin to become green (40). They could quantify the levels of
P2X4 at the plasma membrane, in acidic compartments and
within undeﬁned additional compartments (40). While the
relative amounts of P2X4-pHluorin at the plasma membrane

EXPRESSION AND TRAFFICKING OF THE
P2X4 RECEPTOR
Trafﬁcking of the P2X4 receptor between the plasma membrane
and endo-cellular compartments has been studied by several
groups. Recently, the role of the P2X4 receptor in lysosomal
membrane trafﬁc and fusion has been thoroughly reviewed (29).
Royle et al. (30) have identiﬁed a motif in the carboxy-terminus
of P2X4 that controls the constitutive and agonist-regulated
internalization of P2X4. When they mutated the following
tyrosine-motif (Y378XXGL) of P2X4, they observed a decrease
in receptor internalization associated with an increase in plasma
membrane expression of P2X4 (30). They also compared the two
tyrosine-motifs (Y372xxV and Y378xxGL) located within the Cterminus of P2X4. They found that the canonical motif
(Y372xxV) is not used for endocytosis of the homomeric P2X4
receptor, while the mutation of the non-canonical one
(Y378xxGL) efﬁciently diminished internalization (31). They
also showed that a synthetic peptide corresponding to a
sequence of P2X4 (VEDYEQGLSG) co-crystallized with the m2
subunit of the clathrin adaptor protein 2 (AP2), and binds to m2
like the canonical YXXF motifs (31). Qureshi et al. (32) showed
that P2X4 is preferentially localized in lysosomes in primary cells
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Williams et al. (44) have produced a large panel of mAb to
human and murine P2X4 that have signiﬁcant inhibitory or
stimulatory properties. Among the inhibitory mAbs, one can
block hP2X4 currents efﬁciently. This antibody, IgG #151, was
subjected to mutagenesis of its VH and VL CDR3 loops, followed
by several rounds of selection to obtain an optimized mAb with
increased binding afﬁnity. The optimized mAb, IgG #151 LO,
blocked hP2X4 more efﬁciently than the original IgG #151. IgG
#151 LO had an IC50 of 0.7 nM, while IgG #151 had an IC50 of
1.2 mM (44). Since none of the 6 anti-human P2X4 inhibitory
mAb reacted with murine P2X4, the authors immunized rats
with puriﬁed full length murine P2X4 receptor and HEK cells
expressing mP2X4. After immunization, rat hybridomas were
produced and 4000 clones were screened for speciﬁc binding to
mP2X4. Among the 251 mAb that bound P2X4, 41 had
inhibitory properties and 18 potentiated mP2X4 currents. The
most powerful inhibitor, IgG #191, was selected and used to
determine whether this mAb could decrease the mechanical
hyperalgesia in a murine model of neuropathic pain (44). IgG
#191 was injected subcutaneously or intrathecally into mice that
underwent partial sciatic nerve ligation. Intrathecal injection of
IgG #191 reduced signiﬁcantly neuropathic pain, when
compared with an isotype control IgG. Subcutaneous injections
had no effect on hyperalgesia, suggesting that peripheral P2X4
receptors might not be implicated in this mouse model of pain.
Interestingly, the same authors had previously produced an
antibody (BBBt0626) which can be transferred across the blood
brain barrier (BBB) into the central nervous system (CNS). Thus,
they created constructs of IgG #191 in which one scFV of
Bbbt026 was linked to each C terminus of the CH3 domain of
IgG#191. The IgG #191Bbbt026 fusion mAb was injected
subcutaneously to different groups of mice, which suffered
from neuropathic pain. A very signiﬁcant dose-dependent
reduction of hyperalgesia was observed in mice treated with
IgG#191Bbbt026 and not in a control group injected with isotype
control antibody fused to Bbbt026. This experiment shows that
IgG#191Bbbt026 could cross the BBB and keep its anti-P2X4
inhibitory properties, and suggests a therapeutic potential as they
can reverse neuropathic pain in vivo (44).
Using a DNA vaccine approach, Bergmann et al. (45)
immunized rat and llamas to produce rat monoclonal
antibodies and llama nanobodies reacting with human, murine
and rat P2X4 receptor. They used an expression vector encoding
the P2X4Y378F mutant, which, unlike the wild-type receptor, has
lost its ability to be internalized and thus is expressed at the cell
surface on transfected cells. They were able to produce several rat
anti-P2X4 mAbs, Nodu 225 and Nodu 246, which only react
with murine P2X4 and two other mAbs (Nodu 19 and Nodu
344), which only bind to human P2X4. They fully characterized
one of them (Table 1). Nodu 246 speciﬁcally reacted with mouse
P2X4 in immunohistochemistry, ﬂow cytometry and
immunoprecipitation assays; it labeled various P2X4+/+ cells
and immunoprecipitated P2X4 from P2X4+/+ bone marrow
derived macrophages (BMDM), while Nodu 246 did not react
with P2X4-/- cells and lysates used as controls. Interestingly,
Nodu 246 labeled weakly non-permeabilized BMDM but gave a

and in acidic compartments depended on the cell type analyzed,
acidic compartments always contained a larger fraction of P2X4
(40). This new methodology provides a powerful imaging tool to
study the P2X4 cellular distribution and trafﬁcking under
various conditions.

MONOCLONAL ANTI-P2X4 ANTIBODIES
Studies on P2X4 biology had been hampered by a lack of selective
pharmacological inhibitors and monoclonal antibodies (mAb)
against P2X4. However, both obstacles have now been overcome
because various panels of mAbs (see Table 1) and good P2X4
inhibitors have become available, as reviewed elsewhere (46–48).
We refer the readers to a recent review for more details on
agonists, antagonists, positive allosteric modulators, negative
modulators, as well as EC50 or IC50 in different species, and
P2X cross-reactivity (48).
In the following paragraph, we summarize the immunological,
biochemical and functional characteristics of several monoclonal
antibodies reacting with P2X4 from different species (Table 1).
The ﬁrst mAb described can recognize the extracellular domain
(ECD) of rat P2X4 in its native conformation. This mAb
immunoprecipitates a protein speciﬁcally recognized by
polyclonal antibodies reacting with a C-terminal epitope of
P2X4. This mAb reacts with P2X4 only and does not react with
the other six P2X receptors (41). More recently, another mAb that
recognizes the extracellular domain of rat P2X4 was produced
after immunization of BALB/c mice with the refolded
extracellular domain of rat P2X4. This mAb reacts in Western
blots with the rat ECD of P2X4 and not with the human one (42).
This mAb speciﬁcally recognizes and immunoprecipitates the rat
P2X4 of transfected human astrocytoma. However, this mAb has
not been tested in immunochemistry and ﬂow cytometry assays
(42). Paalme et al. (43) have produced several mouse mAb after
immunization of C57BL/6 mice with the ECD of human P2X4.
The three following mAb (mAb19, mAb27 and mAb 29 see Table
1) could immunoprecipitate the human and mouse P2X4 from
lysates of HEK cells stably transfected with different constructs of
human P2X4 or mouse P2X4 (43). Flow cytometry analysis of
transfected cells, and immunoprecipitation and
immunohistochemistry experiments demonstrated that these
mAbs speciﬁcally recognize P2X4 in its native conformation.
Flow cytometry analyses showed that mAb27 reacts with
macrophages of wild-type animals and not with those from
P2X4-deﬁcient mice (43). In addition, mAb27 does not label
HEK cells expressing the human P2X7 receptor, demonstrating
its speciﬁcity for P2X4. Importantly, these mAb were used to
characterize the expression of P2X4 receptor on mouse and
human peripheral blood lymphocytes (PBL). The highest P2X4
surface expression level was found on eosinophils from PBL and
could be a useful marker for this cell type in conjunction with
Siglec-8. Using mAb27, the expression levels of P2X4 on PBL
from human and mice were signiﬁcantly higher on male
leucocytes than on female ones. This sex difference in the two
different species needs further investigation.
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mAb or Nanobody

Mouse
P2X4

Mouse IgM mAb anti-P2X4
Mouse mAb anti-P2X4

Human
P2X4

Rat
P2X4

Cross-reacts with other P2X

—

+++
+++

No cross-reaction with all P2X (1,2,3,5,6,7)
ND

+++

Does not label P2X4 KO cells and does not
react with human P2X7

Immunoprecipitation

Immunoprecipitates the rat P2X4
Immunoprecipitates the
extracellular domain of
rat P2X4
Immunoprecipitates human P2X4
Immunoprecipitates mouse and
human P2X4
Immunoprecipitates mouse and
human P2X4

Reacts with P2X4 in
Western-blot

Activation or
Inhibitionof P2X4
Activity

References

No
Reacts with rat P2X4

ND
ND

Bo X. et al. (41)
Igawa et al. (42)

No
No

No
No

Paalme et al. (43)
Paalme et al. (43)

No

No

Paalme et al. (43)

Inhibits human P2X4
Inhibits P2X4.
Reduces mechanical
hyperalgesia
Inhibits P2X4.
Reduces mechanical
hyperalgesia

Williams et al. (44)
Williams et al. (44)

7

mAb 19 anti-P2X4 (IgG2b)
mAb 27 anti-P2X4 (IgG2b)

ND
+++

+++
+++

mAb 29 anti-P2X4 (IgM)

+++

+++

IgG#151 LO
IgG#191

No
+++

+++

IgG#191-Bbbt0626

+++

Nodu 225
Mab Rat anti-P2X4
Nodu 246
mAb Rat anti- P2X4
Nodu 19
mAb Rat anti-P2X4
Nodu 344
mAb Rat anti-P2X4
Nb 262
Nb 284
Nb 318
Nb 325
Nb 271
Nb 258
Nb 301

+++

—

+++

—

—

+++

No

—

+++

No

Bergman et al. (45)
Bergman et al. (45)
Bergman et al. (45)

+++

+++
+++
+++

No
No
No
No
No
No
No

Bergman
Bergman
Bergman
Bergman
Bergman
Bergman
Bergman

+++
+++
+++

+++
+++
+++

No cross-reaction with all the other P2X

Immunoprecipitates mouse P2X4
not human P2X4
Immunoprecipitates mouse P2X4
not human P2X4

+++
+++
+++
human & mouse P2X7

No
No

Kanellopoulos et al.
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TABLE 1 | Available antibodies against P2X4.

Williams et al. (44)

Bergman et al. (45)
None

Bergman et al. (45)

et
et
et
et
et
et
et

al. (45)
al. (45)
al. (45)
al. (45)
al. (45)
al. (45)
al. (45)
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very strong ﬂuorescent signal if BMDM were permeabilized
before addition of the ﬂuorochrome-labeled mAb. This
observation is in agreement with the intracytoplasmic
lysosomal localization of P2X4. Seven anti-P2X4 nanobodies
were obtained and the seven VHH were cloned in an
expression vector to link directly the VHH to the hinge, CH2
and CH3 domains of rabbit IgG producing a divalent-nanobody
rabbit IgG with increased avidity. Using HEK cells expressing
human, rat or mouse P2X4 and human or murine P2X7 (as
control of speciﬁcity), they showed that Nb262 and Nb301 react
with human P2X4 only (Table 1). Two nanobodies (Nb271 and
284) bind to human, rat and mouse P2X4, while one (Nb 258)
recognizes human and mouse P2X4 (Table 1).
Interestingly, a powerful inhibitor of P2X4 (IgG #191) has
been used to treat some P2X4-dependent diseases. A similar
strategy has been used by Danquah et al. (49) who have produced
a llama nanobody with potent antagonist effect against P2X7.
This nanobody inhibited P2X7 functions of macrophages and T
lymphocytes and, when injected in vivo, decreased inﬂammation
in two mouse disease models: experimental glomerulonephritis
and allergic contact dermatitis (49).

that P2X4 and P2X7 interacted functionally. In contrast, two
separate studies, using rat or mouse P2X4 and P2X7, claimed that
P2X4 and P2X7 do not co-assemble to produce P2X4/P2X7
heterotrimers (52, 53). P2X4 or P2X7 complexes from lysates of
different tissues were separated on blue native (BN)-PAGE and
detected by immunoblotting using anti-P2X4 and anti-P2X7
speciﬁc antibodies. The results showed that P2X4 and P2X7 are
trimeric complexes but there was no evidence of P2X4/P2X7
heterotrimers. In addition, overexpression of P2X4 and P2X7 in
Xenopus oocytes showed that P2X4/P2X7 heterotrimers were not
found (52).
In agreement with these ﬁndings, using BN-PAGE and two
different chemical cross-linkers, Boumechache et al. (53) studied
the subunit content of P2X4 and P2X7 complexes expressed by
primary cultures of rat microglia and macrophages from wild
type and P2X7-deﬁcient mice. They observed in cell lysates
treated with disuccinimidyl suberate and plasma membrane
cross-linked with a membrane-impermeant cross-linker that
P2X4 or P2X7 complexes were homotrimers. While these two
studies are convincing, one cannot completely rule out the
possibility that a very small percentage of P2X4/P2X7
heterotrimers co-assemble but are not detected. As mouse
parotid acinar cells express P2X4 and P2X7 receptors, a
laboratory (54) compared the electrophysiological properties of
ATP-stimulated currents in acinar cells with HEK293 cells
transfected with mouse P2X4 or P2X7 cDNA or with different
mixtures of P2X4/P2X7 cDNA ratios. They found that
electrophysiological and pharmacological properties of P2X4and P2X7-homomers expressed in HEK293 cells were different
from those observed in HEK293 cells and in mouse acinar cells
co-expressing P2X4/P2X7. These ﬁndings led the authors to
hypothesize that the interaction of murine P2X4 and murine
P2X7 is due to the assembly of heterotrimeric P2X4/P2X7
complexes with novel electrophysiological properties, to an
interaction between homomeric P2X4 and P2X7 receptors, or a
combination of both mechanisms.
More recently, the interaction of P2X4 and P2X7 subunits was
reassessed using two different strategies: measurements of Förster
resonance energy transfer (FRET), and analyses of ATP-activated
ion currents in Xenopus oocytes transfected with human P2X4 or
P2X7 or with both human P2X4 and P2X7. Thus, P2X4 and P2X7
subunits labeled with EGFP and TagRFP ﬂuorescent proteins,
respectively, were co-expressed in the oocytes. This allowed
Schneider et al. (55) to determine whether a close physical
interaction between P2X4 and P2X7 occurred. Signiﬁcant FRET
signals were measured with P2X4 and P2X7 labeled with EGFP or
TagRFP in their extracellular domains or in their C-terminal
regions. On the basis of these results, the authors concluded that
P2X4 and P2X7 subunits were assembled as heterotrimers. Using
the two-electrode voltage clamp technique, they then examined
whether the human P2X4 and P2X7 subunits, co-transfected in
Xenopus oocytes, produced a new electrophysiological phenotype
due to a functional interaction. Surprisingly, they found that at low
ATP concentrations only human P2X4 receptors were activated,
while at high ATP concentrations, human P2X7, with low ATP
afﬁnity, became stimulated. In addition, the effects of P2X4- and

PHYSICAL INTERACTIONS BETWEEN
P2X4 AND P2X7
The study by Torres et al. (50) was the ﬁrst to determine whether
the seven members of the P2X family can associate as homomers
or heteromers. For this purpose, they produced rat P2X subunits
tagged with different epitopes and transfected them in HEK cells
alone or associated as pairs to examine whether they could form
homomers or heteromers, respectively. They found that all
subunits except P2X6 can co-assemble to produce homomers.
P2X7 also forms homomers but is unable to associate with any
other P2X receptor. In contrast, P2X4 receptors form heteromers
with P2X5 or P2X6. These conclusions were revisited by Guo
et al. (51) who provided biochemical and electrophysiological
data indicating that rat P2X4 and P2X7 can form heteromeric
receptors. They co-expressed P2X4-tagged and P2X7 in HEK cells
and immunoprecipitated P2X4 with an anti-tag antibody. They
found that P2X7 was co-immunoprecipitated with P2X4. To
eliminate an artifact due to overexpression of P2X4 and P2X7
in HEK, they also used BMDMs. Immunoprecipitation of P2X4
endogenous receptors with anti-P2X4 allowed them to detect
P2X7 at the expected molecular weight in Western-blots with
anti-P2X7 antibodies. They also provided additional evidence
showing that when P2X4 and P2X7 were co-expressed,
ivermectin, an allosteric modulator of P2X4, could confer
ivermectin-responsiveness to BzATP, a ligand of P2X7.
Furthermore, co-expression of P2X7 with P2X4 in HEK cells
modiﬁed the responses observed with BzATP (P2X7 agonist) and
MgATP (P2X4 agonist). When P2X4 or P2X7 were expressed
alone in HEK cells, stimulation with BzATP or MgATP induced
large currents in HEK-P2X7 or HEK-P2X4 cells, respectively. In
contrast, in HEK cells expressing both receptors, the currents
triggered by both agonists were diminished, strongly suggesting

Frontiers in Immunology | www.frontiersin.org

8

March 2021 | Volume 12 | Article 645834

Kanellopoulos et al.

Structure and Function of P2X4

P2X7-speciﬁc pharmacological drugs on oocytes co-expressing
human P2X4 and human P2X7 strongly suggested that no
functional interaction occurred and that co-expression of P2X4
and P2X7 does not generate a new electrophysiological phenotype
different from that of P2X4 or P2X7 alone. More recently, Trang
et al. (56) used murine microglial BV-2 cells and the whole cell
voltage clamp technique to determine whether P2X4 and P2X7
receptors are activated independently or interact molecularly and/
or functionally. Using the selective pharmacological P2X4 (PSB15417) and P2X7 (A438079) inhibitors, they found strong
inhibition of the current, demonstrating that no P2X receptors
other than P2X4 and P2X7 are responsible for the ATP-dependent
currents in BV-2 cells. They further analyzed P2X4 and P2X7
mediated current components with or without P2X4 and P2X7
receptor pharmacological inhibitors and compared the current
kinetics. Their results showed that P2X4 and P2X7 are activated
independently, strongly suggesting that P2X4/P2X7 heteromers
are not formed. They also treated BV-2 cells with the proinﬂammatory molecules LPS and interferon-g (IFN-g) to induce
an M1 phenotype in vitro. Only the simultaneous treatment with
LPS and IFN-g induced a signiﬁcant increase in P2X4 current
components, while P2X7 receptor dependent ones remained
unchanged. These results also argue against a model in which
physical or functional heteromerization of P2X4 and P2X7
receptor protomers takes place.
Importantly, the studies of Antonio et al. (57) suggested that
interpretation of biochemical results indicating that
heterotrimers of P2X4/P2X7 exist requires additional tests such
as chemical cross-linking experiments conﬁrming heteromer
formation and atomic force microscopy (AFM) imaging.
Indeed, in their studies, a close interaction between rat P2X4
and P2X7 was suggested in cells using the in situ proximity
ligation assay and by co-immunoprecipitation from detergent
lysates or co-puriﬁcation by afﬁnity (57). However, when
detergent lysates of membranes from cells co-transfected with
rat P2X4-HA and rat His10-P2X7 were treated with the chemical
cross-linker disuccinimidyl suberate, immunoprecipitation with
anti-HA antibody did not reveal the presence of heterotrimers.
Moreover, AFM was used to generate images of single receptors
isolated from cells expressing P2X4 or P2X7 and P2X4/P2X7.
The results of AFM experiments indicated that interaction
between P2X4 and P2X7 was due to association of
homotrimers and not to the production of heterotrimers.
Presently, despite great efforts to determine whether P2X4
and P2X7 interact as heterotrimers or homotrimers, there is no
deﬁnitive proof in favor of one model or the other. However,
several publications show that functional interactions between
P2X4 and P2X7 do occur (see below).

selective pore formation, phosphorylation of MAPKinase ERK1/2
and p38, and cell death. Using sh-RNA to silence P2X4, ATP
stimulation of RAW264.7 cells leads to a strong decrease in the
early burst of Ca2+ inﬂux and a signiﬁcant inhibition of cell death,
while non-selective pore formation and MAPkinase activation
were not affected. Since stimulation of P2X4 alone does not trigger
cell death, these results strongly suggest that co-expression of
P2X4 with P2X7 promotes P2X7-dependent macrophage death.
Further studies on RAW264.7 cells conﬁrmed that P2X4
potentiates P2X7-dependent release of IL-1b and HMGB1
through an early increase in Ca2+ inﬂux boosting the Ca2+
inﬂux following P2X7 stimulation (58). These studies in a
murine macrophage cell line were extended to BMDC (59). In
LPS-stimulated BMDC, the stimulation of P2X7 by ATP triggers
NLRP3-dependent activation of caspase 1, which is involved in the
proteolytic cleavage of pro-inﬂammatory cytokines IL-1b and IL18. BMDC express P2X4 and P2X7 which, after ATP stimulation,
triggers Ca2+ inﬂux. The sh-RNA silencing of P2X4 induced a
signiﬁcant decrease in the Ca2+ inﬂux and a down-modulation of
IL-1b and IL-18 release (59). Overall, these studies suggest that
P2X4 can positively control P2X7-dependent Ca2+ inﬂuxes and
potentiates inﬂammation via P2X7-dependent maturation of proinﬂammatory cytokines.
Interestingly, the role of P2X4 in an ovalbumin (OVA)-driven
model of allergen-induced airway inﬂammation (AAI) was
studied by Zech et al. (60), who showed that P2X4 expression
in the lung increased in mice suffering from AAI as compared
with control littermates. This increase in P2X4 was also found in
cells in the broncho-alveolar lavage ﬂuid (BALF) of asthmatic
individuals compared with healthy individuals. The involvement
of P2X4 in AAI was clearly established because treatment of
sensitized mice with the selective P2X4 pharmacological
inhibitor 5-BDBD (benzodiazepine derivative, 5-(3bromophenyl)-1,3-dihydro-2H-benzofuro[3,2-e]-1,4-diazepin2-one) decreased inﬂammation, and P2X4-deﬁcient mice
developed a less severe AAI compared with wild-type controls.
Thus, in 5-BDBD treated mice and in P2X4-deﬁcient animals, a
signiﬁcant reduction of the number of BALF cells was found as
well as a decrease in production of IL-4, IL-5 and IL-13 by
mediastinal lymph node cells after allergen boost (60). ATP
stimulation of allergen sensitized BMDCs of WT mice triggered
the release of IL-1b as expected, but in BMDCs from P2X4deﬁcient animals, a signiﬁcant decrease of IL-1b production was
observed. Interestingly, in allergen-sensitized wild-type BMDCs,
there was a signiﬁcant increase in P2X7 mRNA expression,
which is not found in BMDCs from P2X4-deﬁcient mice.
Thus, these results suggest that P2X4, in addition to its effect
on early burst of Ca2+ inﬂux, triggers upregulation of P2X7,
which contributes to increased production of IL-1b (60).

FUNCTIONAL INTERACTIONS BETWEEN
P2X4 AND P2X7

ROLE OF P2X4 IN MAST CELL
DEGRANULATION

Kawano et al. (58) have studied the role of P2X4 in P2X7dependent cell death of RAW264.7 mouse macrophages. They
found that stimulation of P2X7 induces a calcium inﬂux, non-
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for its activation. Signal 1 requires stimulation by a pathogenassociated molecular pattern (PAMP), such as LPS, which leads
to transcription of NF-kB and upregulation of genes encoding
pro-inﬂammatory cytokines and chemokines, as well as proteins
involved in inﬂammasome assembly. Signal 2 requires
stimulation by a danger-associated molecular pattern (DAMP),
such as HMGB1, IL-1a or extracellular ATP, which results in
inﬂammasome activation (64). We and others have extensively
studied the effects of extracellular ATP on the NLRP3
inﬂammasome activation through P2X7 receptor signaling
(65–68). A number of downstream pathways from P2X7
ligation have been described, including efﬂux of K + and
production of reactive oxygen species (ROS) following ligation
of P2X7 by ATP (69, 70). In this review, we will focus our
discussion on mechanisms whereby P2X4 may modulate
inﬂammasome activation in different tissues.
Our group and others previously reported that P2X4 interacts
with P2X7 and shares some functional features with P2X7 (58,
59). We demonstrated that the P2X4 receptor is functionally
associated with the P2X7 receptor and pannexin-1 in gingival
epithelial cells (GEC) and modulates ATP-induced ROS
production (70). After infection of GEC with Porphyromonas
gingivalis, ATP-induced IL-1b secretion was inhibited by P2X4
receptor antagonists and P2X4 depletion. This suggests that
P2X4, by physically interacting with P2X7 and pannexin-1,
modulates NLRP3 inﬂammasome activation.
Since P2X4 is expressed in several tissues, P2X4 could
conceivably modulate inﬂammasome activation in different
tissues and clinical conditions. In rat urothelial cell line (MYP3
cells), hydrostatic pressure induced ATP release and intracellular
caspase-1 activation (71). Treatment with P2X4 antagonists had
no effect on ATP release but it inhibited pressure-induced
caspase-1 activation. Moreover, the P2X4 receptor antagonist
also inhibited ATP-induced caspase-1 activation in MYP3 cells,
suggesting that the inﬂammasome may be activated through
P2X4 receptor in urothelial cells (71). A recent study showed that
the P2X4 receptor exacerbated ischemic acute kidney injury
through activation of the NLRP3 inﬂammasome (72). In this
study, P2X4-deﬁcient mice showed signiﬁcantly attenuated
NLRP3 inﬂammasome signaling after renal ischemia and
reperfusion, compared with wild-type controls. Using human
proximal tubule cells and proximal tubule cells derived from
wild-type or P2X4-deﬁcient mice, the authors also demonstrated
that P2X4 agonists induced expression of IL-1b and NLRP3
mRNA, while a P2X4 antagonist inhibited ATPgS-induced
NLRP3 and IL-1b mRNA expression (72). Another study
demonstrated that heme, the hemoglobin component that is
released when hemolysis or extensive cell damage occurs,
activates the NLRP3 inﬂammasome in macrophages through
P2X7 and P2X4 (73). Using gene-silencing techniques, the
authors showed that heme activated caspase-1 and IL-1b
through P2X7 and P2X4 (73). Another group demonstrated
that P2X4 and NLRP3 were highly expressed and these two
proteins co-localized in renal tubule cells of type 2 diabetic
patients with nephropathy (74). The authors also showed that
the P2X4 signaling pathway mediated NLRP3 inﬂammasome

These cells contain large granules which, after exocytosis, release
numerous chemical mediators involved in allergic reactions such
as serotonin, histamine, heparin and various proteases. Yoshida
et al. (61) have studied the role of P2X4 in mouse bone-marrow
derived mast-cell (BBMC) degranulation. They showed that
BBMC express several P2 ionotropic receptors such as P2X1,
P2X4 and P2X7. Among these receptors, only P2X7 can trigger
degranulation upon ATP stimulation. This effect is P2X7-speciﬁc
because it could be blocked by pre-incubation of mast cells with
the P2X7 pharmacological inhibitor, AZ10606120. Mast-cells
expressing the high afﬁnity receptor for IgE can bind antigenspeciﬁc IgE which, after cross-linking by multivalent antigen,
induces rapid degranulation. Interestingly, P2X4 stimulation by
low doses of ATP does not trigger degranulation directly but
potentiates the BBMC degranulation induced by cross-linking of
the high-afﬁnity IgE receptor (FcϵRI). The ATP-potentiation of
degranulation is blocked by the P2X4-speciﬁc pharmacological
inhibitor, 5-BDBD, or by P2X4-speciﬁc siRNA knock-down in
BBMC. In recent studies, Yoshida et al. (62) evaluated the role of
P2X4 in mast-cell degranulation triggered by cross-linking of
IgE-FcϵRI complexes by antigen using BBMC of wild-type and
P2X4-deﬁcient mice. They found that ATP stimulation of wildtype BBMC potentiates antigen-triggered degranulation, while
this effect was strongly reduced in BBMC from P2X4-deﬁcient
mice. Importantly, the potentiating effect of ATP is recovered
when P2X4-deﬁcient BBMC are transfected with a P2X4encoding plasmid. Cross-linking IgE-FcϵRI complexes by
antigen leads to the recruitment and activation of the tyrosinekinase Syk which triggers the phosphorylation of phospholipase
Cg (PLCg) and Akt. Yoshida et al. (62) found that ATP
stimulation enhanced antigen-induced phosphorylation of Syk
and PLCg in BBMC from wild-type mice, while this
phenomenon was diminished in P2X4-deﬁcient BBMC. Since
stimulation of BBMC by ATP alone did not activate Syk and
PLCg, the potentiating effect of ATP must be mediated by P2X4.
Intriguingly, the potentiating effect of P2X4 on phosphorylation
of Syk and PLCg was found to be independent of Ca2+ inﬂux
(62). This raises the following question: how can P2X4 activation
potentiate FcϵRI phosphorylation cascades independently of ion
channel activity?

ROLE OF P2X4 RECEPTOR IN
INFLAMMASOME ACTIVATION AND
INFLAMMATION
Inﬂammasomes are multi-protein cytoplasmic platforms that
assemble in the host-cell cytosol after detecting stress, infection
and sterile insults. Activation of inﬂammasomes can lead to
maturation and secretion of the pro-inﬂammatory cytokines IL1b and IL-18, and activation of an inﬂammatory form of cell
death called pyroptosis (63). There are several inﬂammasomes,
which are named after the pathogen recognition receptor (PRR)
involved in detection of the stress/infection, such as NLRP3,
NLRP1b, AIM2 and NLRC4. The NLRP3 inﬂammasome is the
most studied inﬂammasome and typically requires two signals
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expression and caspase-1/IL-1b/IL-18 production in HK-2 cells
(an immortalized proximal tubule epithelial cell line from
human kidney) (74). These studies suggest that, not only the
P2X7 receptor, but also the P2X4 signaling pathway can activate
the NLRP3 inﬂammasome in the kidneys and that P2X4 may be
an important therapeutic target in renal disease.
In a mouse model of spinal cord injury, P2X4-deﬁcient mice
presented impaired inﬂammasome signaling in the spinal cord,
which resulted in decreased levels of caspase-1 and IL-1b, but not
IL-18 (75). The P2X4-deﬁcient animals also showed decreased
inﬂammatory cell inﬁltration and an improvement in functional
outcomes after spinal cord injury. A separate study showed that
the envelope glycoprotein 120 (gp120) of human
immunodeﬁciency virus type 1 (HIV-1) induced pyroptotic
cell death, IL-1b and IL-18 secretion, as well as an increase in
expression of NLRP1 and P2X4 in satellite glial cells of dorsal
root ganglia (76). Depletion of P2X4 decreased all these
inﬂammasome measurements, suggesting that gp-120 can
activate the inﬂammasome in the cells of the central nervous
system through P2X4 (76). Comparing microglia and BMDM, it
was found that ATP-induced IL-1b secretion in BMDM was fully
dependent on P2X7 signaling, while in microglia, multiple
purinergic receptors were involved, including P2X4 and P2X7
(77). These studies suggest that P2X4 may be a possible
therapeutic target during neurodegenerative disorders.
In a mouse model of arthritis, P2X4 inhibition led to a
decrease in caspase-1, ASC, and NLRP1 and consequently a
decrease in IL-1b production (78). The authors suggested that
the P2X4 inhibitor attenuated the severity of arthritis in mice due
to inhibition of the NLRP1 inﬂammasome.
Taken together, these results suggest that P2X4 may play an
important role in inﬂammasome activation in several organs and
systems of the body including the central nervous system, oral
cavity, kidneys and blood cells, even if it does so to a lesser extent
than the P2X7 receptor. The P2X4 receptor may therefore serve
as a therapeutic target for several clinical conditions involving
inﬂammasome activation.
P2X4 also has other functions associated with inﬂammation.
P2X4 triggers the secretion of inﬂammatory mediators including
two pain inducers, prostaglandin E2 (PGE2) and brain-derived
neurotropic factor (BDNF) (79, 80). Both of these pain signaling
pathways are therefore linked to increased cell surface expression
of P2X4. In particular, P2X4 mediates PGE2 release by tissueresident macrophages. During PGE2 biosynthesis, arachidonic
acid (AA) is released from membranes by phospholipase A2
(PLA2), a reaction controlled by calcium, hence potentially by
ATP and P2X4. Interestingly, P2X4-deﬁcient mice show a
complete absence of inﬂammatory PGE2 in tissue exudates,
indicating that P2X4 may be the main trigger of inﬂammationinduced PGE2 synthesis in vivo (81). In fact, both neuropathic
and inﬂammatory pain are correlated with P2X4 expression at
the cell surface of microglia/macrophages. Interestingly, an
increased surface density of P2X4 receptors on neurons
reduces anxiety and affects spatial memory, as shown using a
conditional transgenic knock-in P2X4 mouse line (82).
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P2X4 is also involved in neutrophil chemoattraction. In
macrophages, ATP is one of the danger molecules that induce
intercellular P2 receptor signaling. Thus, P2X4 modulates ATPinduced macrophage CXCL5 expression and secretion, which is
important for neutrophil recruitment to the inﬂammation site
(83). Moreover, while platelets are the main source of CXCL5
under homeostatic conditions, CXCL5 is also produced by lung
epithelial cells in order to attract neutrophils. In humans, CXCL5
is a proinﬂammatory chemokine that regulates CXCR2dependent neutrophil trafﬁcking and directed migration.

THE P2X4 RECEPTOR AND SEPSIS
Sepsis is a life-threatening organ dysfunction resulting from
dysregulated host responses to infection (84). This syndrome is
one of the leading causes of deaths globally, and represents a
major public health issue with considerable economic
consequences (85). In 2017, the World Health Organization
deﬁned prevention and treatment of sepsis a global health
priority, given that the management of this syndrome is
complex, including restoration of tissue perfusion via ﬂuid
administration and antimicrobial therapy (85). Increased
plasma ATP levels found in mouse model for sepsis (86) and
patients with sepsis suggests that purinergic receptors may be
ligated and play a role during this condition (87). Here, we
discuss what is known about the involvement of P2X4 in sepsis.
The ﬁrst study to describe the role of P2X4 during sepsis used
the a-hemolysin-producing Escherichia coli mouse infection
model of sepsis. The authors demonstrated that P2X7-deﬁcient
or P2X4-deﬁcient mice had lower survival rates, higher cytokine
levels and activated intravascular coagulation, compared with
wild-type controls (88). To explain the high levels of cytokines,
including IL-1b, in the receptor-deﬁcient mice, the authors
showed that cytokine production was dependent on caspase-8
and RIPK3 as an alternative to the P2X7-dependent caspase-1
pathway. This study suggested that activation of P2X4 and P2X7
plays a protective effect against sepsis during infection with
uropathogenic E. coli (88).
A second study addressed the role of P2X4 in the sepsis
mouse model of cecal ligation and puncture (CLP) (89). In this
study, P2X4-deﬁcient mice showed a lower survival rate,
increased bacterial burden and higher level of inﬂammatory
cytokines and chemokines in the blood and peritoneum
compared with wild-type controls (89). In addition, they
produced mice in which the P2X4 gene was speciﬁcally deleted
in myeloid cells, and found that in these mice sepsis was more
severe with increased bacterial burden and elevated cytokine
levels when compared with control mice. This idea is supported
by in vitro data showing that ATP-induced E. coli killing in
infected macrophages depends on P2X4 through mitochondrial
ROS production (89). These data suggest that P2X4 in
macrophages is protective and suppresses bacterial
dissemination and inﬂammation in vivo.
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TCR simulation, and that activated mitochondria translocated
to the immune synapse (95). Thus, the ampliﬁcation of TCR
signals at the immune synapse results from the accumulation of
ATP-producing mitochondria, the presence of pannexin-1
involved in ATP release, and of P2X1 and P2X4 receptors
which increase Ca2+ inﬂux in response to ATP. More recently,
Ledderose et al. (96) studied the role of the chemokine CXCL12
and its impact on purinergic signaling and TCR stimulation.
CXCL12 binds to the chemokine receptor CXCR4, which is
expressed on T lymphocytes. They found that CXCL12
stimulation of naive CD4+ T cells triggers cell migration and
rapid release of ATP into the extracellular space. siRNAsilencing of Pannexin-1 in Jurkat T cells abolished cell
migration and ATP release (96). In addition, blocking of
mitochondria with carbonyl cyanide m-chlorophenyl
hydrazine, an inhibitor of oxidative phosphorylation,
inhibited ATP release and migration of T cells after CXCL12
stimulation. Furthermore, they showed, using sophisticated
live-cell imaging, that mitochondrial Ca2+ uptake and ATP
release were localized at the front of polarized cells and
pseudopod protrusion (96). Since P2X1, P2X4, and P2X7
receptors are all expressed by CD4+ T cells, the authors
identiﬁed the P2X receptor involved in T cell migration
induced by CXCL12, using speciﬁc pharmacological
inhibitors. They found that P2X4 inhibition by 5-BDBD has
the strongest inhibitory effect on T cell migration, CD69
expression, and CD4+ T cell proliferation, while inhibition of
P2X1 and P2X7 has a weaker effect on CD4+ T cells (96).
Interestingly, after T cell stimulation, P2X4 receptors were
concentrated at sites of pseudopod protrusion with activated
mitochondria. Thus, an autocrine purinergic pathway
modulates mitochondrial activity, which in turn activates
P2X4 receptor leading to pseudopod formation and T
cell migration.
In the continuation of their previous work, Ledderose et al.
studied the role of the purinergic receptor P2Y11 in the
migration of human T lymphocytes (97). The P2Y11 receptor
is a G-protein coupled receptor which, after binding of extracellular ATP, induces the production of the second messenger cAMP, which stimulates protein-kinase A. The stimulation of
CXCR4 chemokine receptor by CXCL12 induces a quick release
of ATP by T lymphocytes. Inhibition of P2Y11 by a selective
pharmacological inhibitor or siRNA silencing blocked the
migration of human CD4+ T cells or of Jurkat cells following
CXCL12 treatment. Similarly, siRNA silencing of P2X4 or
inhibition of P2X4 by 5-BDBD inhibited T cell migration
induced by CXCL12. Thus, P2X4 and P2Y11 receptors are
required for T cell migration induced by CXCL12 (97). In
addition, P2Y11 receptors are localized at the posterior part of
the cell, where they negatively modulate the activity of
surrounding mitochondria. At the other pole of the T cell,
mitochondrial ATP production ampliﬁes P2X4 receptor
activity (Ca 2+ inﬂux), which boosts mitochondrial ATP
synthesis. The ATP production triggers actin cytoskeleton reorganization required for pseudopod protrusion and T cell

ROLE OF P2X4 IN T CELL RECEPTOR
SIGNALING AND T CELL MIGRATION
Several studies have shown that T cell receptor (TCR)
stimulation triggers ATP release in the extracellular milieu
through plasma membrane hemi-channels such as pannexin 1
on T lymphocytes (90, 91). Several P2X receptors are expressed
on T lymphocytes: P2X7 (90, 91), P2X1, and P2X4 (92).
Woehrle et al. (92) studied the role of P2X receptors in the
control of T cell activation following TCR stimulation induced
by anti-CD3 and anti-CD28 antibodies coupled to microbeads.
They observed that P2X1 and P2X4 translocate rapidly to the
immune synapse, formed by T cells and microbeads, and
persist at the synapse for 1 hour after cell stimulation. In
contrast, P2X7 receptors do not translocate to the synapse and
remain evenly distributed at the plasma membrane. When cells
from the human T cell leukemia line Jurkat are stimulated by
anti-CD3 and anti-CD28 antibodies, siRNA silencing of P2X1
or P2X4 or P2X7 receptors inhibits Ca2+ signaling. Using
pharmacological inhibitors of P2X1 and P2X4, they also
found that Ca2+ signaling was inhibited in human primary
CD4 + T cells triggered by anti-CD3/CD28 antibodies.
Interestingly, they showed that P2X1 and P2X4 are involved
in NFAT activation and interleukin-2 production after TCR
stimulation. However, pharmacological inhibition of P2X4
always induces a higher inhibition of NFAT and IL-2
production than P2X1 inhibition by NF023 (a selective
inhibitor of P2X1). It is worth noting that inhibition of P2X7
receptors was shown to decrease Ca2+ signaling and IL-2
transcription by two different laboratories (90, 91). Thus,
P2X1, P2X4, and P2X7 receptors participate in TCRmediated T lymphocyte activation. Interestingly, Woehrle
et al. (92) observed that pannexin-1 translocates to the
immunological synapse very quickly after TCR/CD28
stimulation, while it is evenly distributed at the plasma
membrane on resting T lymphocytes. Furthermore,
pharmacological inhibition of pannexin-1 decreased Ca2+
signaling and IL-2 transcription in response to TCR
stimulation. Thus, Woehrle et al. (92) argue that, since P2X1
and P2X4 are found at the immunological synapse with
pannexin-1, these receptors are preferentially involved in T
cell activation. This interpretation is strengthened by their
observation that STIM1 and Orai1 are present at the
immunological synapse with P2X1, P2X4, and pannexin-1
(92). STIM1 and Orai1 are molecular constituents of
CRAC channels, which play a major role in T cell activation
(93, 94). Overall these data, obtained mostly with human T
lymphocytes or Jurkat cells stimulated by anti-CD3/CD28
antibodies coupled to microbeads, showed that TCR
stimulation is ampliﬁed by purinergic signaling at the
immunological synapse.
Ledderose et al. (95) identiﬁed the endocellular origin of
ATP released after TCR stimulation on T lymphocytes by antiCD3/CD28 antibody-coated beads. They showed that increased
production of ATP by mitochondria occurred rapidly after
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Most of these studies were performed with human T
lymphocytes or Jurkat cells activated principally by anti-CD3/
CD28 antibodies coupled to microbeads or stimulated by
CXCL12. It is important to determine whether similar
purinergic signaling occurs in murine models. In particular,
the physiological interactions between murine T lymphocytes
and antigen presenting cells (APC) could be tested in vitro and in
vivo using TCR–transgenic mouse lines speciﬁc for a deﬁned
antigen and another mouse line constitutively expressing the
same antigen in APC. In addition, conditional knockout mice in
which one can control the timing and tissue distribution of P2X4
receptor expression (available at EUCOMM/Genoway) could be
used to delineate the role of P2X4 in physiological or
pathological conditions at the immunological synapse. Thus,
eliminating P2X4 expression (or other P2X receptors) from T
lymphocytes or dendritic cells (professional APC) may shed light
on their ability to amplify TCR responses, depending on their
presence on T cells or APC.

migration. It is worth noting that mice do not express P2Y11
receptors (98). Thus, it would be interesting to determine
whether another mouse P2Y receptor is able to functionally
replace the human P2Y11 receptor and trigger c-AMP/proteinkinase A activity.
The studies described in the previous paragraphs were
performed with T lymphocytes bearing the ab TCR. Thus,
Manohar et al. (99) determined whether purinergic signaling
could amplify TCR responses of non-conventional T
lymphocytes expressing gd TCR. Using puriﬁed gd T cells from
human peripheral blood, they found that stimulation with antiCD3/CD28 antibodies coupled to microbeads induced rapid
release of ATP, reaching a maximal concentration 30 seconds
after stimulation. They showed using pharmacological inhibitors
that inhibition of pannexin-1 and connexin hemichannels
blocked ATP release after TCR stimulation. In addition,
inhibition of vesicular exocytosis with Brefeldin A signiﬁcantly
decreased ATP release, suggesting that this pathway is also
involved in ATP release to the extracellular space. The authors
also found that these lymphocytes express A2A, P2X1, P2X4,
P2X7 and P2Y11 receptors (99). To determine which purinergic
receptor may impact gd T cell responses, they studied the
expression of CD69, an early T cell activation marker, and the
increase in TNF-a and IFN-g mRNA transcripts following TCR
stimulation after pharmacological inhibition of P2X1, P2X4,
P2X7 and P2Y11 (99). They found that only P2X4 blockade
inhibited TNF-a and IFN-g transcription in response to gd T cell
stimulation with anti-CD3/CD28 coated beads (99). Thus, they
concluded that ATP release and autocrine signaling via P2X4
receptors are involved in the modulation of gd T cell responses.

P2X4 AND FUNCTION/DISEASE OF
SPECIFIC ORGANS
P2X4 is expressed ubiquitously and modulates disease in various
organs such as heart, kidney, liver, lung and CNS (Figure 3). In
the following paragraphs, we review the role of P2X4 in the
lungs, kidney, liver and auto-immune diseases of the nervous
system. We refer readers to recent reviews on the role of P2
receptors in distal lungs for more details and informative

FIGURE 3 | Pleiotropic effects of P2X4 on different organs and diseases.
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illustrations (4), cardiovascular disease (48), neuropathic pain
(47, 100) and CNS function and pathophysiology (101).

Efﬁcient gas exchange and surfactant function depend on
regulation of the alveolar surface liquid volume and composition
(4). The activation of P2Y2 receptors by luminal nucleotides
induce Cl- secretion and inhibit Na+ absorption, leading to ﬂuid
secretion. On the other hand, FACE via P2X4 receptor promotes
ﬂuid resorption in response to surfactant secretion (4). It was
described that P2X4 induces an inward cation current (via
FACE), which in turn leads to apical-to-basolateral ﬂuid
transport (106). The localized alveolar ﬂuid resorption
temporarily decreases the level of alveolar surface liquid, which
helps maintain an adequate environment for efﬁcient gas
exchange and lung function.

P2X4 and Lungs
The P2X4 receptor has been described to be involved in lung
function, speciﬁcally in vesicular release of lamellar bodies
containing surfactant and surfactant release, control of fusion
pore expansion and epithelial ﬂuid resorption. Alveoli are found
at the end of the bronchioles and are responsible for gas
exchange. The alveolar epithelium comprises two main cell
types: the alveolar type I (ATI) and alveolar type II (ATII) cells
(102). ATI cells express P2X7 and P2Y2 receptors (4), cover
>95% of the alveolar surface (103), and are responsible for
efﬁcient gas exchange between the alveolus and the pulmonary
capillaries. ATII cells express P2X4, P2X7, P2Y2 and P2Y6
receptors (4). ATII cells synthesize, store and release
pulmonary surfactant into the alveolar lumen, where they act
to reduce the surface tension and optimize conditions for gas
exchange (4, 102).
ATII cells contain lamellar bodies, which are large lysosomerelated organelles with an acidic lumen that stores surfactants
(104). Studies have shown that the P2X4 receptor is expressed on
the surface of lamellar bodies in ATII cells, and is involved in the
secretion and activation of surfactants (105, 106). Miklavc et al.
reported that once lamellar bodies fuse with the plasma
membrane to exert exocytosis, P2X4 receptors located in the
vesicle promote fusion pore opening and exocytic content release
in ATII cells (105). Unlike many readily-soluble molecules,
surfactants are not immediately released following fusion of
lamellar bodies with the plasma membrane (4). Once lamellar
bodies fuse with the plasma membrane, P2X4 receptors located
in the lamellar body are transiently activated and generate a
localized cytosolic Ca2+ signal in the immediate vicinity of the
fused lamellar body, which was termed as fusion-activated Ca2+
entry (FACE) (105). P2X4-induced FACE leads to an increase in
intracellular Ca2+ at the fusion site, which is required for the
fusion pore expansion. The expansion of the pore facilitates the
release of the poorly soluble surfactant from the lamellar body to
the alveolar lumen (4).
It was later demonstrated that the lamellar body itself carries
all that is necessary (ion channel and its ligand) to promote pore
expansion and surfactant release (107). Fois et al. showed that
lamellar bodies store ATP, and that these molecules activate
vesicular P2X4 receptor in an autocrine manner upon exocytosis,
once the fusion pore is open in the plasma membrane of ATII
cells (107). It is important to note that lamellar bodies have an
acidic pH of approximately 5.5, and P2X4 receptors are strongly
inhibited under low pH conditions (104). Thus, upon opening of
the fusion pore, the intraluminar pH of lamellar bodies is
neutralized, which then allows P2X4 receptors to be activated
by ATP under neutral pH conditions. It has also been suggested
that P2X4 activation and FACE are part of a positive feedback
loop, in which the increase in Ca2+ concentrations near the
cellular plasma membrane leads to additional lamellar body
fusion (4, 108). These studies demonstrate the importance of
the P2X4 receptor in the secretion of pulmonary surfactant and
control of fusion pore expansion in ATII cells.
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P2X4 and Kidneys
Renal ischemia/reperfusion is a common etiology of acute kidney
injury (AKI). It is a consequence of a defect in oxygen and
nutrient supply to kidney cells, resulting in an accumulation of
metabolic waste. This may lead to proximal tubular cell death by
apoptosis/necrosis associated with inﬂammatory responses and
inﬁltration of various leukocytes. Among DAMP molecules
released by dead cells, ATP can ligate P2 receptors. P2X7 is
barely expressed in normal kidney cells but can aggravate several
kidney diseases such as acute kidney injury, diabetic
nephropathy, septic AKI, and chronic kidney disease (109–
112). However, P2X7 receptor expression increases during
kidney inﬂammation, which can account for its effects in
several kidney diseases. Surprisingly, while P2X4 is expressed
in normal kidney cells (113), its role in kidney diseases has not
been well deﬁned yet.
As mentioned above in the section on inﬂammasomes and
P2X4, in several kidney diseases when NALP3 inﬂammasome
activation is involved in the physiopathology, P2X4 was found to
exacerbate the disease. However, P2X4 does not always
exacerbate pathology in kidneys. The role of P2X4 in unilateral
ureteric obstruction (UUO), a rodent model of chronic
interstitial inﬂammation and ﬁbrosis, has been studied by Kim
et al. (113). Higher accumulation of collagen ﬁbrils, and higher
expression of transforming growth factor-b and connective
tissue growth factor mRNAs, was found in kidney tissues from
UUO-operated P2X4-deﬁcient mice, compared with wild-type
control (113). In contrast, after UUO, comparison of UUOoperated kidneys showed a signiﬁcant decrease in tubulointerstitial damage characteristic of obstructive nephropathy in
P2X7-deﬁcient animals compared with wild-type animals (114).
Thus, the lack of P2X4 results in signiﬁcant enhancement of
kidney tubulo-interstitial damage and ﬁbrosis after UUO (113).

P2X4 and Liver
Purinergic signaling in the liver in health and disease has been
reviewed by Burnstock et al. (115). Different cell subsets in the
liver express various P2 purinoreceptors of the P2Y and P2X
families (115). P2X4 and P2X7 are well represented in various
liver cell types, implying that these receptors may have important
functions in liver physiology and/or physiopathology. It has
previously been shown that partial hepatectomy (PH) in rats
induces a rapid and short-lived ATP release from liver in blood
and bile (116). This is due to mechanical stress following the
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strong increase in blood pressure in the liver and portal vein after
elimination of two thirds of the hepatic blood vessels. ATP is
released by Kupffer cells because removal of these cells by
clodronate treatment correlates with a decrease of ATP in the
hepatic vein (116). In addition, using quinacrine to stain ATP
containing cell compartments, Gonzales et al. (116) showed that
hepatocytes contain ATP-enriched lysosomes. After PH,
contents of these ATP-containing lysosomes were released,
probably by lysosome exocytosis (116). Importantly, ATP
release correlates with hepatocyte cell cycle progression; and
treatment of rats with PPADS, a pharmacological inhibitor of P2
purinoreceptors, inhibits liver regeneration (116). These
experiments strongly suggest that P2X4 signaling may be
involved in liver recovery after PH.
The same authors studied the role of P2X4 during acute and
chronic liver injury (35, 117). They found that, in hepatocytes,
P2X4 is expressed in ATP-containing lysosomes and that liver
regeneration after PH is delayed in P2X4-deﬁcient mice
compared with wild-type animals. They showed that the
absence of P2X4 does not alter hepatocyte proliferation but
increases liver injury after PH, i.e. hepatocyte necrosis and
cholestasis (35). After PH, P2X4-deﬁcient mice show a
decrease in bile ﬂow with an increase of HCO−3 in bile, which is
associated with a signiﬁcant drop in biliary pH when compared
with wild-type animals (35). In addition, modiﬁcations of
lysosome biogenesis and early inﬂammatory reactions were
found in P2X4-deﬁcient mice after PH (35, 117).
In a model of liver chronic injury i.e. bile duct ligation
(BDL), Le Guilcher et al. (117) studied the role of P2X4 in liver
ﬁbrogenesis associated with hepatic myoﬁbroblasts responsible
for the production of exaggerated extracellular matrix
components. They showed that P2X4 is strongly expressed in
hepatocyte myoﬁbroblasts and controls myoﬁbroblast
contraction, adhesion and migration when BDL-induced
ﬁbrosis was compared in P2X4-deﬁcient and wild-type mice
(117). The pro-ﬁbrogenic effects of P2X4 in BDL are due to
lysosomal exocytosis from hepatocyte myoﬁbroblasts, leading
to the release of proﬁbrogenic/proﬁbrolytic components such
as IL-6, PDGFb and VEGF-A, MMPs and TIMPs. Exocytosis of
lysosomes also contribute to the release of ATP that had been
stored in P2X4-expressing lysosomes. This may trigger P2X4dependent activation of hepatocyte myoﬁbroblasts. Thus, these
results indicate that blocking P2X4 should inhibit ﬁbrogenesis
and may be considered as an anti-ﬁbrosis strategy for
treatment of chronic liver disease.

EAE. They found that P2X4 is upregulated at the peak of EAE
and persisted during the recovery phase. In addition, they
observed that Interferon regulatory factor (Irf)-8 and Irf-5
transcription factors (121, 122) were upregulated at the peak
and recovery phases of EAE, and that their levels were
consistent with the expression level of P2X4. On the basis of
their previous work (119), they hypothesized that P2X4
inhibition should prevent microglial death and recruitment of
inﬂammatory monocytes at early stages of EAE induction.
Nonetheless, in apparent disagreement with their hypothesis,
blockade of P2X4 by daily injection of the P2X4 antagonist
TNP-ATP exacerbated EAE disease (120). Importantly, they
showed that EAE severity was increased in P2X4-deﬁcient mice
and that TNP-ATP treatment did not modify the course of the
disease in P2X4-deﬁcient animals. As myelin clearance is
necessary for remyelination and phagocytosis/remyelination
is dependent on microglia polarization, the authors compared
gene expression in the lumbar spinal cord of vehicle- and TNPATP injected mice at the peak and recovery phase of EAE. They
found that inhibition of P2X4 only increased the proinﬂammatory genes d uring EAE and induced proinﬂammatory polarization of microglia, leading to a decrease
in myelin phagocytosis by microglia and low remyelination of
oligodendrocytes. Importantly, Zabala et al. (120) used
ivermectin, a positive potentiator of P2X4, to evaluate its
therapeutic potential in EAE. When this drug was
administered daily after the onset of EAE, a signiﬁcant
improvement of the motor deﬁcits and of the axon
conduction latencies in the corticospinal tract were observed.
The effect of ivermectin on in vitro microglial polarization
showed that pro-inﬂammatory genes decreased while antiinﬂammatory genes increased. In addition, ivermectin
triggered endosome-lysosome fusion and increased
phagocytic activity, potentiating myelin degradation and
stimulating remyelination. The action of ivermectin was
P2X4-speciﬁc because it was not observed in P2X4-deﬁcient
microglia. These results suggest that ivermectin, a drug already
approved for use in human parasitic diseases, should be tested
for treatment of MS.

P2X4 AS A MEDIATOR OF ETHANOL
ACTION
P2X4 ligand-gated ion channels are the most highly-expressed
and most ethanol-sensitive P2X receptors in the central nervous
system (123) and also mediate the main effect of ethanol on the
brain (124). Alcohol increases P2X4 expression on the cell
surface (125) and, at the same time, inhibits signaling via P2X4
receptors (126). P2X4 activity is selectively blocked by ethanol,
which acts as a negative allosteric modulator that blocks the open
channel (123, 127).
P2X2 and P2X4 expressed in Xenopus oocytes can inhibit
ATP-associated currents at toxic and anesthetic concentrations
of ethanol (127). However, ethanol inhibition does not depend
on either voltage or ATP concentration but may alter the

P2X4 and Experimental Autoimmune
Encephalomyelitis (EAE): An Animal Model
of Multiple Sclerosis
ATP is highly concentrated inside cells under physiological
conditions. It belongs to the family of DAMPs that are released
by stressed cells or after cell lysis (118).
P2X4 is expressed at high levels in activated microglia of rats
with EAE and in the optic nerves of multiple sclerosis (MS)
patients (119). Thus, Zabala et al. (120) studied the role of P2X4
during myelin-oligodendrocyte glycoprotein (MOG)-induced
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together, these ﬁndings suggest that alcohol consumption
may be modulated through P2X4, and that ivermectin or
ivermectin analogs have the pharmacological potential to
reduce alcohol consumption and preferences (5).

receptor afﬁnity for ATP (123). Using the whole-cell patchclamp technique in HEK293 cells, ethanol was found to inhibit
P2X4 channel opening by affecting receptor function at amino
acid residues Asp331 and Met336 in the ectodomain of
transmembrane region 2 (TM2). The results also showed that
ethanol inhibits P2X4 channel function through a mechanism
different from that of other P2XRs (123). Modeling data further
suggest that these residues may be part of the alcohol interaction
pocket (128). However, it is not possible to distinguish between
ethanol interacting directly with Asp331/Met336 residues and
ethanol interacting with separate loci that alter the channel
conformation at these positions, making the channel unable to
bind ethanol (123).
It is noteworthy that these same amino acids also play a role
in the interaction of ivermectin with P2X4. Ivermectin can
antagonize the inhibitory effect of ethanol on P2X4 and is
thought to interfere with ethanol binding to the channel (128).
Trp46 in the TM1 segment of the receptor has also been shown
to contribute to the formation of a putative binding pocket (129).
Recent studies conﬁrm that ethanol has several binding sites on
the P2X4 receptor - high afﬁnity binding sites and low afﬁnity
binding sites. First, high-afﬁnity sites (such as position Met336)
that are sensitive to the lower intoxicating concentrations
experienced by most social drinkers, and second, low-afﬁnity
sites (such as positions 46 and 331) that show responses to higher
alcohol concentrations achieved by alcoholics. Taken together,
these results suggest that there is a direct interaction between
ethanol and P2X4, which may have a signiﬁcant effect on alcohol
use disorders (126).
The results of a genomic study suggest that P2X4 may play a
role in alcohol consumption and preference in mice and rats.
Rodents lacking the P2RX4 gene drink more ethanol than wildtype counterparts (126). In particular, whole brain expression of
the P2RX4 gene is inversely related to alcohol preference and
P2X4 mRNA expression is reduced in alcohol-preferring
rats (130).
Interestingly, purinergic receptors, such as P2X4, can affect
satisfying and repulsive neural chains – in particular, those
involving dopamine, thereby involving these receptors in
modulating the addictive synaptic signal. Therefore, P2X4 may
be an important therapeutic target in the treatment of alcohol
abuse behavior (128). P2X4 activity has also been implicated in
other behaviors associated with dopaminergic neurotransmission,
including motor control and the handling of sensory
information (131).
Alcohol is known to cause structural and functional
disorders in microglial cells, which include phagocytosis, cell
proliferation, and migration. For example, P2X4 is signiﬁcantly
upregulated in microglial cells after exposure to ethanol.
Interestingly, after ethanol treatment, both microglial
phagocytosis and migration toward CX3CL1 decrease in a
P2X4-dependent fashion (125). A recent publication reports
that an ethanol-sensitive component of ATP is mediated by
P2X4, since the ventral tegmental area neurons are inhibited by
ATP, and ethanol antagonizes this inhibition (132). Taken
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POLYMORPHISMS OF HUMAN P2X4
Genetic polymorphisms may lead to a gene sequence variation
that is neutral, or promotes gain- or loss-of-protein function.
Some genetic variations can affect clinical conditions in which
relevant proteins are slightly modiﬁed, leading to a decrease or
increase in disease susceptibility. The P2RX7 gene is highly
polymorphic in humans, showing at least eight nonsynonymous single nucleotide polymorphisms (SNPs) that can
lead to a functional effect on the P2X7 receptor (133). The
human P2RX4 gene is located on chromosome 12q24.32 (134)
and has 12 exons. The human P2RX4 gene may present four
non-synonymous SNPs, in which three of them have no
signiﬁcant effects on the receptor, but one leads to a loss-offunction P2X4 receptor (135).
The loss-of-function polymorphism (Tyr315Cys) in the
P2RX4 gene was associated with increased susceptibility to agerelated macular degeneration (AMD) in a study of 744 patients
and 557 age-matched Caucasians (136). Interestingly, haplotype
analysis showed that the P2X4 315-Cys minor allele co-inherited
with P2X7 150-Arg was present 4-fold more often in patients
with AMD than control subjects. Reduced phagocytic activity
was observed in cells expressing both P2X4 315-Cys and P2X7
150-Arg variants, which led the authors to speculate that a
decrease in macrophages/microglia phagocytic functions, and
therefore a decrease in debris clearance, may contribute with the
onset of AMD (136).
The P2X4 receptor is abundantly expressed in endothelial
cells and is required for optimal ﬂow-sensitive mechanisms that
regulate blood pressure and vascular remodeling (137).
Additionally, P2X4-deﬁcient mice present reduced endothelial
cell responses to blood ﬂow and develop hypertension (137),
suggesting that a loss-of-function polymorphism in the P2XR4
gene in humans could affect blood pressure. In fact, one study
showed that genetic variations in P2X4 (and also P2X7) are
linked with a small but signiﬁcant effect on blood pressure in a
Caucasian population (138). A different group reported that a
loss-of-function polymorphism in the P2X4 receptor
(Tyr315>Cys, the same mutation described in the study
regarding AMD) signiﬁcantly reduced ATP-induced inward
currents at the cellular level, which is likely due to alterations
in the agonist binding site of the receptor (135). Analysis of this
genetic variant in 2874 subjects demonstrated that the
Tyr315>Cys mutation was signiﬁcantly associated with pulse
pressure. The increase in pulse pressure may be a reﬂection of
P2X4 loss-of-function conferred by the Tyr315>Cys mutation
(135). In fact, using human umbilical vein endothelial cells
(HUVECs), a separate study demonstrated that kruppel-like
factor 2 (KLF2) is involved in shear stress regulation through
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risks for developing HIV-associated sensory neuropathy, blood
pressure complications, osteoporosis, multiple sclerosis, and
impaired immune responses. Since most of the studies were
conducted in a Caucasian cohort population for a limited
number of diseases, future studies will evaluate the role of
P2RX4 gene variants in different races, and whether the P2RX4
gene plays a role in other pathological conditions.

P2X4 activation. Transfection of P2RX4 loss-of-function genetic
variant Tyr315>Cys into human endothelial cells blocked ATPinduced KLF2 expression. These studies suggest an important
role for P2X4 in endothelial cell-modulated blood
pressure regulation.
Analysis of SNP polymorphisms in the P2RX4 gene suggested
an association of this gene with susceptibility to HIV-associated
sensory neuropathy (139), even though there was a stronger
association of the disease with the P2X4 contiguous gene,
CAMKK2. The authors suggested that polymorphisms in the
P2RX4 gene and association with HIV-associated sensory
neuropathy may be due to the role of P2X4 in pain (139) and
the fact that some patients presenting speciﬁc P2RX4 alleles had
increased TNF-a concentrations in their PBMC (140), which
contributes to the onset of disease.
The fact that P2X4 is expressed in both osteoclasts and
osteoblasts suggests a role for this receptor in bone physiology.
A study evaluated patients with fractures (690 females and 231
males) and found that subjects carrying the loss-of-function
Tyr315Cys genetic variant presented decreased bone mineral
density values and showed 2.68-fold higher risk of osteoporosis
compared with controls (141). The same group previously
showed that a P2X7 SNP is associated with decreased bone
mineral density values (141). However, whether P2X4 and P2X7
SNPs synergistically contribute to increase the risk of
osteoporosis is still unclear.
P2RX7 variants resulting in loss-of-function were found to
be protective against multiple sclerosis, whereas variants
conferring gain-of-function increased the risk of disease
(142). A separate study evaluated 197 multiple sclerosis
patients and 100 control subjects and identiﬁed a P2RX7P2RX4 haplotype containing three rare missense mutations
associated with high incidence of multiple sclerosis (143).
Sadovnick et al. (143) identiﬁed 3 variants (P2X7 T205M,
P2X7N361S, P2X4 G135S) that co-segregate with MS in one
family where 6 individuals out of 13 were affected by the
disease. When expressed in HEK293 cells, they found that
P2X7 T205M had lost its plasma membrane expression and
phagocytic activity (143). In contrast, the function of P2X7
N361S was undistinguishable from WT P2X7. The P2X4 G135S
mutant expressed in HEK293 cells was associated with an
increase in ATP-induced inward currents and a higher
response to Ca2+, compared with wild-type P2X4 (143). Thus,
the P2X7 T205M variant has a strong impact on P2X7 function,
while the two other mutations have a minor effect on P2X4P2X7. Additional studies are required to determine whether
these two rare variants (P2X7 N361S, P2X4 G135S) are also risk
factors in MS in the absence of P2X7 T205M.
Altogether, studies from this section suggest that subjects
carrying genetic variants of the P2RX4 gene may have higher

CONCLUSION
Most studies on purinergic function until now have focused
primarily on P2X7. Less is known about the function of P2X4
under normal conditions and during pathogenesis. Comparisons
between the two receptors is facilitating the structural
characterization of P2X4. Nonetheless, the contribution of
P2X4 to disease states appears to be mostly different from the
role of P2X7, and the tissue distribution for the two receptors is
different. Polymorphisms in the P2RX4 gene has led to
discoveries about the possible function of P2X4 in human
physiology. Little is known about the role of P2X4 in
modulating inﬂammation and in immune responses to
infection. Further studies in the future should shed light on the
function of this understudied purinergic receptor.
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